36 / 38
Primary Objective: 1 year PFS Rates
Odds Ratio: 70% vs 85%
PARSIFAL STRATEGY: First Line ER[+] MBC
Phase II-randomized trial
FULVESTRANT HD (500) +
PALBOCICLIB (3w/4)
LETROZOLE +
PALBOCICLIB (3w/4)
PD
1:1
Stratification factors:
•
Visceral disease
•
Adjuvant AI
Open Label
Postmenopausal
MBC ER[+]
HER2[-]
AI Sensitive
FIRST LINE ET
N = 464 patients